<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">
 <list list-type="simple" id="ulist0010">
  <list-item id="u0010">
   <label>•</label>
   <p id="p0020">Introduce the concept of risk assessment in travel and a framework for assessing the immunosuppressed traveler</p>
  </list-item>
  <list-item id="u0015">
   <label>•</label>
   <p id="p0025">Give a brief overview of different types of immunosuppression used to treat autoimmune diseases and their mechanisms of action. Particular consideration will be given to biologic drugs, especially TNF-alpha blockers. Other forms of immunosuppression used in autoimmune conditions such as steroids and methotrexate will also be discussed.</p>
  </list-item>
  <list-item id="u0020">
   <label>•</label>
   <p id="p0030">Discuss the implications of different forms of immunosuppression for travel vaccinations and travel-related infection risk</p>
  </list-item>
  <list-item id="u0025">
   <label>•</label>
   <p id="p0035">Discuss vaccine preventable and nonvaccine preventable infections related to travel</p>
  </list-item>
  <list-item id="u0030">
   <label>•</label>
   <p id="p0040">Discuss noninfectious issues applicable to all travelers including those who are immunosuppressed</p>
  </list-item>
 </list>
</p>
